Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Comparative Trial of Permethrin, Ivermectin, and Combination Therapy for Scabies
2024-520348-40-00Phase 4Authorised
- Sponsor
- Giuliani
- Start
- Jul 2025
- Modality
- Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in scabies comparing Topical permethrin (Scabiacid) monotherapy, Oral ivermectin (Ivermectina Giuliani) monotherapy and Combination therapy: topical permethrin + oral ivermectin (3 arms). Primary endpoint: Complete cure rate (CCR) at week 1. Planned start Jul 2025; status: authorised.
02
Drugs
permethrinivermectin
03
Conditions
scabies
Beyond the preview
Go deeper on 2024-520348-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520348-40-00.